Drug
Recombinant staphylokinase
Recombinant staphylokinase is a pharmaceutical drug with 5 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
1(20%)
Results Posted
50%(2 trials)
Phase Distribution
Ph phase_4
3
60%
Ph phase_3
2
40%
Phase Distribution
0
Early Stage
0
Mid Stage
5
Late Stage
Phase Distribution5 total trials
Phase 3Large-scale testing
2(40.0%)
Phase 4Post-market surveillance
3(60.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
5
all time
Status Distribution
Active(1)
Completed(4)
Detailed Status
Completed4
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 32 (40.0%)
Phase 43 (60.0%)
Trials by Status
completed480%
recruiting120%
Recent Activity
1 active trials
Showing 5 of 5
completedphase_3
Single Bolus Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase in Patients With AIS
NCT03151993
completedphase_3
Single Bolus Recombinant Nonimmunogenic Staphylokinase Versus Single Bolus Tenecteplase (Metalyse) in STEMI
NCT02301910
recruitingphase_4
Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction
NCT05410925
completedphase_4
Prolonged Clinical Follow-up of OPTIMA-5
NCT05649696
completedphase_4
The OPTIMA-5 Trail
NCT05023681
Clinical Trials (5)
Showing 5 of 5 trials
NCT03151993Phase 3
Single Bolus Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase in Patients With AIS
NCT02301910Phase 3
Single Bolus Recombinant Nonimmunogenic Staphylokinase Versus Single Bolus Tenecteplase (Metalyse) in STEMI
NCT05410925Phase 4
Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction
NCT05649696Phase 4
Prolonged Clinical Follow-up of OPTIMA-5
NCT05023681Phase 4
The OPTIMA-5 Trail
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5